These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37529870)

  • 21. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
    Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
    Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.
    Yuan X; Gao Z; Yang C; Duan K; Ren L; Song G
    Front Endocrinol (Lausanne); 2023; 14():1170881. PubMed ID: 37342259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    Thompson AM; Trujillo JM
    Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
    Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
    Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
    Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
    Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
    Tuchscherer RM; Thompson AM; Trujillo JM
    Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.
    Monami M; Dicembrini I; Nreu B; Andreozzi F; Sesti G; Mannucci E
    Acta Diabetol; 2017 Dec; 54(12):1101-1114. PubMed ID: 28932989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.
    Chen H; Li XZ; Chen JQ; Ren TS; Zhang YS; Wang YN; Zhao QC
    Medicine (Baltimore); 2023 Jul; 102(27):e34122. PubMed ID: 37417602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
    Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
    Zhang YS; Weng WY; Xie BC; Meng Y; Hao YH; Liang YM; Zhou ZK
    Osteoporos Int; 2018 Dec; 29(12):2639-2644. PubMed ID: 30083774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Semaglutide once-weekly: improved efficacy with a new safety warning.
    Coon SA; Crannage EF; Kerwin LC; Guyton JE
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.
    Liu Y; Zhang X; Chai S; Zhao X; Ji L
    J Diabetes Res; 2019; 2019():1534365. PubMed ID: 31396537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
    Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
    Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.
    Heimbürger SM; Brønden A; Johansen NJ; Dejgaard TF; Vilsbøll T; Knop FK
    Expert Opin Pharmacother; 2019 Apr; 20(5):501-510. PubMed ID: 30730773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.
    Vukajlovic T; Sailer CO; Asmar A; Jensen BL; Vogt DR; Christ-Crain M; Winzeler B
    J Clin Endocrinol Metab; 2022 May; 107(6):e2581-e2589. PubMed ID: 35134170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
    Madsbad S; Holst JJ
    Cardiovasc Res; 2023 May; 119(4):886-904. PubMed ID: 35925683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
    Owens DR; Monnier L; Bolli GB
    Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.